NeuroMetrix Inc
Change company Symbol lookup
Select an option...
NURO NeuroMetrix Inc
MIRM Mirum Pharmaceuticals Inc
FCELB Fuelcell Energy Inc
UK Ucommune International Ltd
CRDF Cardiff Oncology Inc
TRNR Interactive Strength Inc
OMGA Omega Therapeutics Inc
ACST Acasti Pharma Inc
PYPD PolyPid Ltd
ACRX AcelRx Pharmaceuticals Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

NeuroMetrix, Inc. is a commercial-stage neurotechnology company based in Woburn, Massachusetts. The Company is engaged in designing, building and marketing medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. The Company has two principal product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. The Company’s DPNCheck is its testing technology for peripheral neuropathies. The Company’s Quell is its wearable neuromodulation technology for chronic pain. It refined approximately 200,000 chronic pain patients. Patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

Price
Delayed
$0.6174
Day's Change
-0.0052 (-0.84%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.6313
Day's Low
0.6012
Volume
(Average)

Today's volume of 41,699 shares is on pace to be in-line with NURO's 10-day average volume of 51,902 shares.

41,699

Company Profile

NeuroMetrix, Inc. is a commercial-stage neurotechnology company based in Woburn, Massachusetts. The Company is engaged in designing, building and marketing medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. The Company has two principal product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. The Company’s DPNCheck is its testing technology for peripheral neuropathies. The Company’s Quell is its wearable neuromodulation technology for chronic pain. It refined approximately 200,000 chronic pain patients. Patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
0.74x
Price/Book (MRQ)
0.25x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

September 2023
Current Month
18.4K
Previous Month
26.1K
Percent of Float
0.22%
Days to Cover
0.5036 Days

Share Information

NURO is in a share class of common stock
Float
8.4M
Shares Outstanding
8.6M
Institutions Holding Shares
13
6.74%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Shai N. GozaniChmn.
  • Thomas T. HigginsCFO
  • Bradley M. Fluegel
  • David E. Goodman
  • Nancy E. Katz

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.